微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Pembrolizumab
Pembrolizumab

肿瘤

关键词肿瘤 药物 肺癌

词汇介绍

拓展阅读

解析

Pembrolizumab 

释    义   n. 帕博利珠单抗;派姆单抗;可瑞达;一种治疗癌症的药物

例    句   Additionally, a phase II study is looking at the combination of rituximab and pembrolizumab (Keytruda) for patients with relapsed follicular lymphoma (NCT02446457). 此外,一项二期研究将利妥昔单抗和pembrolizumab联合来治疗复发的滤泡性淋巴瘤(试验注册号是NCT02446457)。

概述

帕博利珠单抗,中文名还有派姆单抗、帕姆单抗,可瑞达。英文名是Pembrolizumab,或者Keytruda,也称为K药。生产厂商是美国默沙东。 获批的全部肺癌适应症与培美曲塞和顺铂/卡铂联合用于一线治疗无法切除、晚期/复发的非鳞状NSCLC患者,无论PD-L1表达如何;与卡铂和紫杉醇/nab-紫杉醇联合用于一线治疗无法切除的、晚期/复发性鳞状NSCLC患者,无论PD-L1表达如何;作为单药,适用于转移性NSCLC患者的一线治疗,其转移性NSCLC的肿瘤具有高PD-L1表达(肿瘤比

Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression复制标题

结外NK/T细胞淋巴瘤的免疫分型: 一种新的生物标志物和疾病进展过程中的免疫转移

发表时间:2019-10-25

影响因子:6.4

作者: Junhun Cho

期刊:Mod. Pathol.

To understand the tumor immune microenvironment, we analyzed the expression of 579 immune-related genes and characterized the immune cells using immunohistochemistries and in situ hybridization for EBER. Based on comprehensive analyses, we developed an immune subtyping model that classifies extranodal NK/T-cell lymphoma patients into four tumor immune microenvironment subgroups using three immunohistochemical markers (FoxP3, PD-L1, and CD68). The four tumor immune microenvironment subgroups were named immune tolerance, immune evasion-A, immune evasion-B, and immune silenced. The immune tolerance group was characterized by high-Treg counts and was frequently observed in early stage, and nasal extranodal NK/T-cell lymphoma. The immune evasion group showed high cytotoxic T-cell counts and high PD-L1 expression but low Treg counts. In the immune-silenced group, almost all immune responses were exhausted, most patients were at an advanced stage, and had the poorest disease prognosis among the tumor immune microenvironment subgroups. In some patients (n = 3), a shift in the tumor immune microenvironment subgroup classification was observed in sequential biopsies. The response rate to pembrolizumab, an anti-PD-1 antibody, was 100% (1/1) in the immune tolerance group, 60% (3/5) in the immune evasion group, and 0% (0/5) in the immune-silenced group.

译文

为了了解肿瘤免疫微环境,我们分析了579个免疫相关基因的表达,并利用免疫组织化学和EBER原位杂交技术对免疫细胞进行了鉴定。在综合分析的基础上,我们建立了一个免疫亚型模型,利用三种免疫组化标记物(FoxP3、PD-L1和CD68)将结外NK/T细胞淋巴瘤患者分为四个肿瘤免疫微环境亚组。四个肿瘤免疫微环境亚群分别为免疫耐受、免疫逃避A、免疫逃避B和免疫沉默。免疫耐受组以高Treg计数为特征,早期常出现,鼻结外NK/T细胞淋巴瘤。免疫逃避组表现出高的细胞毒性T细胞计数和高的PD-L1表达,但Treg计数较低。在免疫沉默组中,几乎所有的免疫反应都被耗尽,大多数患者处于晚期,并且在肿瘤免疫微环境亚群中疾病预后最差。在一些患者(n = 3)中,在连续活检中观察到肿瘤免疫微环境亚群分类的变化。免疫耐受组对抗PD-1抗体pembrolizumab的应答率为100%(1/1),免疫逃避组为60%(3/5),免疫沉默组为0%(0/5)。